BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9790452)

  • 1. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites.
    Sàbat M; Guarner C; Soriano G; Bulbena O; Novella MT; Ortiz J; Ricart E; Villanueva C; Rosello J; Rodríguez J; Balanzó J
    Dig Dis Sci; 1998 Oct; 43(10):2184-9. PubMed ID: 9790452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Kosta P; Papadimitriou K; Tsianos EV
    J Clin Gastroenterol; 2006 Apr; 40(4):342-6. PubMed ID: 16633107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Fotopoulos A; Al Bokharhii J; Pappas C; Katsaraki A; Tsianos EV
    Am J Gastroenterol; 2005 Apr; 100(4):879-85. PubMed ID: 15784036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
    Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Katsaraki A; Tsianos EV
    Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
    Singh V; Dhungana SP; Singh B; Vijayverghia R; Nain CK; Sharma N; Bhalla A; Gupta PK
    J Hepatol; 2012 Feb; 56(2):348-54. PubMed ID: 21749847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
    Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of captopril on renal functions, renal and portal hemodynamics in patients with cirrhosis.
    Tsai YT; Lin HC; Lee FY; Hou MC; Wang SS; Lee SD
    Proc Natl Sci Counc Repub China B; 1996 Apr; 20(2):44-50. PubMed ID: 8931343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects.
    Morillas RM; Planas R; Cabré E; Galán A; Quer JC; Feu F; García Pagán JC; Bosch J; Gassull MA
    Hepatology; 1994 Dec; 20(6):1502-8. PubMed ID: 7982651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites.
    Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Christos P; Paraskevi K; Konstantinos P; Katsaraki A; Tsianos EV
    Dig Dis Sci; 2005 Oct; 50(10):1771-7. PubMed ID: 16187171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide in the treatment of refractory ascites of cirrhosis.
    Kalambokis G; Fotopoulos A; Economou M; Tsianos EV
    Scand J Gastroenterol; 2006 Jan; 41(1):118-21. PubMed ID: 16373285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension.
    Escorsell A; Bandi JC; Andreu V; Moitinho E; García-Pagán JC; Bosch J; Rodés J
    Gastroenterology; 2001 Jan; 120(1):161-9. PubMed ID: 11208725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F; Pantea L; Sniderman K
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of somatostatin on renal function in cirrhosis.
    Ginès A; Salmerón JM; Ginès P; Jiménez W; Saló J; Piera C; Clària J; Rivera F; Arroyo V; Rodés J
    Gastroenterology; 1992 Dec; 103(6):1868-74. PubMed ID: 1360435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study.
    Ludwig D; Schädel S; Brüning A; Schiefer B; Stange EF
    Dig Dis Sci; 2000 May; 45(5):1019-27. PubMed ID: 10795771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites.
    Luca A; Feu F; García-Pagán JC; Jiménez W; Arroyo V; Bosch J; Rodés J
    Hepatology; 1994 Jul; 20(1 Pt 1):30-3. PubMed ID: 8020901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.
    Saló J; Ginès A; Quer JC; Fernández-Esparrach G; Guevara M; Ginès P; Bataller R; Planas R; Jiménez W; Arroyo V; Rodés J
    J Hepatol; 1996 Dec; 25(6):916-23. PubMed ID: 9007721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term administration of isosorbide-5-mononitrate does not impair renal function in cirrhotic patients.
    Salerno F; Borroni G; Lorenzano E; Solenghi D; Cazzaniga M; Bissoli F; Ceriani R; deFranchis R
    Hepatology; 1996 May; 23(5):1135-40. PubMed ID: 8621145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.
    Narahara Y; Kanazawa H; Taki Y; Kimura Y; Atsukawa M; Katakura T; Kidokoro H; Harimoto H; Fukuda T; Matsushita Y; Nakatsuka K; Sakamoto C
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1791-7. PubMed ID: 19686420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dipyridamole on kidney function in cirrhosis.
    Llach J; Ginès P; Arroyo V; Salmerón JM; Ginès A; Jiménez W; Gaya J; Rivera F; Rodés J
    Hepatology; 1993 Jan; 17(1):59-64. PubMed ID: 8423042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.